title: Further available immunization option to prevent pneumococcal disease.
abstract: In their recent review, Charles Feldman and Ronald Anderson provide an overview of various clinical aspects of pneumococcal infections. We would like to complete this report by providing some additional information on a widely-used immunization option, which was not originally mentioned in the article. The protein D pneumococcal conjugate vaccine (PHiD-CV) has been pre-approved by WHO and its impact is supported by real-life data from the regions of its use.
authors: GSK Vaccines, Wavre, 1300, Belgium.
authors: Ivo
authors: I
authors: Vojtek
authors: GSK Vaccines, Wavre, 1300, Belgium.
authors: Bernard
authors: B
authors: Hoet
keywords: PHiD-CV, efficacy, post-marketing surveillance